Not logged in Share Save
Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer - (HERIZON) Tobias, J.; Kundi, M.; Garner-Spitzer, E.; Zielinski, C. C.; Maglakelidze, M.; Andric, Z. G.; Petrovic, Z.; Nikolic, I. V.; Ryspayeva, D.; Bulat, I. V.; Nagarkar, R.; Chawla, T.; Chong, L. O.; Nixon, B.; Yavrom, S.; Ede, N. J.; Wiedermann, U. Share Save
Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants Wagner, Angelika; Garner-Spitzer, Erika; Auer, Claudia; Gattinger, Pia; Zwazl, Ines; Platzer, Rene; Orola-Taus, Maria; Pichler, Peter; Amman, Fabian; Bergthaler, Andreas; Huppa, Johannes B.; Stockinger, Hannes; Zielinski, Christoph C.; Valenta, Rudolf; Kundi, Michael; Wiedermann, Ursula Share Save
Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib plus endocrine therapy in HR+/HER2-metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial Agrawal, Yash; Fernandez-Martinez, Aranzazu; Gil-Gil, Miguel; Zielinski, Christoph; Ruiz-Borrego, Manuel; Ciruelos, Eva; Munoz, Montserrat; Margeli, Mireia; Bermejo, Begona; Anton, Antonio; Kahan, Zsuzsanna; Csoszi, Tibor; Alonso-Romero, Jose L.; Garcia-Saenz, Jose Angel; Sanchez-Rovira, Pedro; Alvarez, Elena; Chacon, J. Ignacio; Gonzalez-Santiago, Santiago; Rodriguez, Cesar A.; Servitja, Sonia; Pfefferle, Adam D.; Herranz, Jesus; Liu, Yuan; Carey, Lisa A.; Romero-Camarero, Isabel; Caballero, Rosalia; Perou, Charles M.; Martin, Miguel Share Save
Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer: Insights from the GEICAM/2013-02 (PEARL) trial Alva, Manuel; Lopez-Tarruella, Sara; Zielinski, Christoph; Ruiz-Borrego, Manuel; Turner, Nicholas; Ciruelos, Eva; Munoz, Montserrat; Bermejo, Begona; Margeli, Mireia; Anton, Antonio; Kahan, Zsuzsanna; Csoszi, Tibor; Casas, Maribel; Murillo, Laura; Murillo, Serafin Morales; Alba, Emilio; Yam, Einav Nili-Gal; Guerrero, Angel; Calvo, Lourdes; de la Haba-Rodriguez, Juan; Ramos, Manuel; Alvarez, Isabel; Garcia-Palomo, Andres; Koehler, Maria; Garcia-Saenz, Jose Angel; Chacon, J. Ignacio; Swift, Claire; Thallinger, Christiane; Gil-Gil, Miguel; Martin, Miguel Share Save
Frontline vaccination with the B-cell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+metastatic or advanced gastric/GEJ adenocarcinoma - Final results from Phase II/HERIZON study Tobias, Joshua; Kundi, Michael; Garner-Spitzer, Erika; Zielinski, Christoph; Maglakelidze, Marina; Andric, Zoran; Petrovic, Zoran; Nagarkar, Rajnish; Chawla, Tanuj; Chong, Leslie Mi Ok; Nixon, Bonnie; Yavrom, Sharon; Ede, Nicholas J.; Wiedermann, Ursula Share Save
Cetuximab every 2 weeks versus standard weekly dosing administration schedule Bokemeyer, Carsten; Ciardiello, Fortunato; Dubreuil, Olivier; Guigay, Joel; Kasper, Stefan; Pfeiffer, Per; Pinto, Carmine; Yamaguchi, Kensei; Yoshino, Takayuki; Zielinski, Christoph; Esser, Regina; Tabernero, Josep Share Save
Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors Tobias, J.; Hoegler, S.; Kundi, M.; Lin, D. Shih-Cheih; Chao, Y.; Garner-Spitzer, E.; Ede, N.; Zielinski, C.; Good, A.; Wiedermann, U. Share Save
HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome Tobias, J.; Kundi, M.; Garner-Spitzer, E.; Zielinski, C.; Maglakelidze, M.; Andric, Z. G.; Petrovic, Z.; Nagarkar, R.; Chawla, T.; Chong, L. O.; Nixon, B.; Yavrom, S.; Ede, N.; Wiedermann, U. Share Save
Share Save
Share Save
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients Pascual, Javier; Gil-Gil, Miguel; Proszek, Paula; Zielinski, Christoph; Reay, Alistair; Ruiz-Borrego, Manuel; Cutts, Rosalind; Ciruelos Gil, Eva M.; Feber, Andrew; Munoz-Mateu, Montserrat; Swift, Claire; Bermejo, Begona; Herranz, Jesus; Margeli Vila, Mireia; Anton, Antonio; Kahan, Zsuzsanna; Csoeszi, Tibor; Liu, Yuan; Fernandez-Garcia, Daniel; Garcia-Murillas, Isaac; Hubank, Michael; Turner, Nicholas C.; Martin, Miguel Share Save
HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome Tobias, J.; Kundi, M.; Garner-Spitzer, E.; Zielinski, C.; Maglakelidze, M.; Andric, Z.; Petrovic, Z.; Nagarkar, R.; Chawla, T.; Chong, L.; Nixon, B.; Yavrom, S.; Ede, N.; Wiedermann, U. Share Save
Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study Subbiah, Vivek; Kreitman, Robert J.; Wainberg, Zev A.; Gazzah, Anas; Lassen, Ulrik; Stein, Alexander; Wen, Patrick Y.; Dietrich, Sascha; Jonge, Maja J. A.; Blay, Jean-Yves; Italiano, Antoine; Yonemori, Kan; Cho, Daniel C.; de Vos, Filip Y. F. L.; Moreau, Philippe; Fernandez, Elena Elez; Schellens, Jan H.; Zielinski, Christoph C.; Redhu, Suman; Passos, Vanessa Q.; Ilankumaran, Palanichamy; Bang, Yung-Jue Share Save
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial Subbiah, Vivek; Kreitman, Robert J.; Wainberg, Zev A.; Gazzah, Anas; Lassen, Ulrik; Stein, Alexander; Wen, Patrick Y.; Dietrich, Sascha; de Jonge, Maja J. A.; Blay, Jean-Yves; Italiano, Antoine; Yonemori, Kan; Cho, Daniel C.; de Vos, Filip Y. F. L.; Moreau, Philippe; Fernandez, Elena Elez; Schellens, Jan H. M.; Zielinski, Christoph C.; Redhu, Suman; Boran, Aislyn; Passos, Vanessa Q.; Ilankumaran, Palanichamy; Bang, Yung-Jue Share Save
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer Guerrero-Zotano, Angel; Belli, Stefania; Zielinski, Christoph; Gil-Gil, Miguel; Fernandez-Serra, Antonio; Ruiz-Borrego, Manuel; Gil, Eva Maria Ciruelos; Pascual, Javier; Munoz-Mateu, Montserrat; Bermejo, Begon; Vila, Mireia Margeli; Anton, Antonio; Murillo, Laura; Nissenbaum, Bella; Liu, Yuan; Herranz, Jesus; Fernandez-Garcia, Daniel; Caballero, Rosalia; Lopez-Guerrero, Jose Antonio; Bianco, Roberto; Formisano, Luigi; Turner, Nicholas; Martin, Miguel Share Save
Share Save
Share Save
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations Caglevic, Christian; Rolfo, Christian; Gil-Bazo, Ignacio; Cardona, Andres; Sapunar, Jorge; Hirsch, Fred R.; Gandara, David R.; Morgan, Gilberto; Novello, Silvia; Garassino, Marina-Chiara; Mountzios, Giannis; Leighl, Natasha B.; Bretel, Denisse; Arrieta, Oscar; Addeo, Alfredo; Liu, Stephen V.; Corrales, Luis; Subbiah, Vivek; Aboitiz, Francisco; Villarroel-Espindola, Franz; Reyes-Cosmelli, Felipe; Morales, Ricardo; Mahave, Mauricio; Raez, Luis; Alatorre, Jorge; Santos, Edgardo; Ubillos, Luis; Tan, Daniel S. W.; Zielinski, Christoph Share Save
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study Martin, Miguel; Zielinski, Christoph; Ruiz-Borrego, Manuel; Carrasco, Eva; Ciruelos, Eva M.; Munoz, Montserrat; Bermejo, Begona; Margeli, Mireia; Csoszi, Tibor; Anton, Antonio; Turner, Nicholas; Casas, Maria, I; Morales, Serafin; Alba, Emilio; Calvo, Lourdes; De La Haba-Rodriguez, Juan; Ramos, Manuel; Murillo, Laura; Santaballa, Ana; Alonso-Romero, Jose L.; Sanchez-Rovira, Pedro; Corsaro, Massimo; Huang, Xin; Thallinger, Christiane; Kahan, Zsuzsanna; Gil-Gil, Miguel Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
CANCER RESEARCH.png)
.png){kind=icon}
Share.png){kind=icon}
Save